Type 2 diabetes detection and management among insured adults by Timothy M. Dall et al.
RESEARCH Open Access
Type 2 diabetes detection and
management among insured adults
Timothy M. Dall1*, Weyna Yang2, Pragna Halder2, Jerry Franz3, Erin Byrne3, April P. Semilla1,
Ritashree Chakrabarti1 and Bruce Stuart4
Abstract
Background: The Centers for Disease Control and Prevention estimates that 28.9 million adults had diabetes in
2012 in the US, though many patients are undiagnosed or not managing their condition. This study provides
US national and state estimates of insured adults with type 2 diabetes who are diagnosed, receiving exams
and medication, managing glycemic levels, with diabetes complications, and their health expenditures. Such
information can be used for benchmarking and to identify gaps in diabetes detection and management.
Methods: The study combines analysis of survey data with medical claims analysis for the commercially insured,
Medicare, and Medicaid populations to estimate the number of adults with diagnosed type 2 diabetes and
undiagnosed diabetes by insurance type, age, and sex. Medical claims analysis used the 2012 de-identified
Normative Health Information database covering a nationally representative commercially insured population,
the 2011 Medicare 5% Sample, and the 2008 Medicaid Mini-Max.
Results: Among insured adults in 2012, approximately 16.9 million had diagnosed type 2 diabetes, 1.45 million
had diagnosed type 1 diabetes, and 6.9 million had undiagnosed diabetes. Of those with diagnosed type 2,
approximately 13.0 million (77%) received diabetes medication-ranging from 70% in New Jersey to 82% in
Utah. Suboptimal percentages had claims indicating recommended exams were performed. Of those receiving
diabetes medication, 43% (5.6 million) had medical claims indicating poorly controlled diabetes-ranging from
29% with poor control in Minnesota and Iowa to 53% in Texas. Poor control was correlated with higher
prevalence of neurological complications (+14%), renal complications (+14%), and peripheral vascular disease
(+11%). Patients with poor control averaged $4,860 higher average annual health care expenditures-ranging
from $6,680 for commercially insured patients to $4,360 for Medicaid and $3,430 for Medicare patients.
Conclusions: This study highlights the large number of insured adults with undiagnosed type 2 diabetes by
insurance type and state. Furthermore, this study sheds light on other gaps in diabetes care quality among
patients with diagnosed diabetes and corresponding poorly controlled diabetes. These findings underscore
the need for improvements in data collection and diabetes screening and management, along with policies
that support these improvements.
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Background
Diabetes is a complex disease that if poorly controlled
increases risk for cardiovascular disease, neuropathy,
retinopathy, nephropathy, and other medical conditions
[1]. The Centers for Disease Control and Prevention
(CDC) estimates that in 2012 the US had 28.9 million
adults (age 20 or older) with diabetes, including 20.8
million with diagnosed diabetes and 8.1 million whose
diabetes was undiagnosed [2]. Among adults with diag-
nosed diabetes (type 1 and type 2), self-reported data cap-
tured through national surveys suggest 86% (17.9 million)
used oral medication or insulin to control glycemic levels,
71% used medication for hypertension, and 65% used
medication for hypercholesterolemia [2]. Diabetes is a
costly disease, and in 2012 was estimated to have contri-
buted to $176 billion in excess medical costs [3, 4]. Type 2
diabetes (T2DM) accounts for 90 to 95% of diabetes cases,
and both T2DM and its complications are potentially pre-
ventable [5]. National statistics suggest a substantial pro-
portion of cases are undiagnosed, untreated, not under
optimal control, and at high risk for complications and as-
sociated medical and indirect costs [6–8].
This study combined survey and medical claims analysis
to address key research questions by state and insurance
type: (1) How many insured adults in 2012 had diagnosed
and undiagnosed T2DM? (2) Among diagnosed T2DM
cases, how many received diabetes medication and recom-
mended exams? (3) Among patients who received diabetes
medication, how many had poorly controlled diabetes as
indicated by ICD-9 diagnosis codes? (4) How did the
prevalence of diabetes complications and annual medical
expenditures differ by diabetes control status? This infor-
mation provides benchmarks to track improvements in
diabetes detection and management as more people in
each state gain insurance coverage under the Affordable
Care Act, as new diabetes screening recommendations are
implemented [9], and as integrated health care systems
seek better ways to improve detection and management.
Methods
The breadth of this study required multiple data sources
and methods, with data covering several years sometimes
combined to increase sample size. Data prior to 2012
were used when 2012 data were unavailable. Estimates of
diabetes prevalence and diagnosed status by state, age,
sex, and insurance type came from national surveys. Ana-
lysis of medical claims provided information on medical
expenditures and the proportion of diabetes cases that
were T2DM, were receiving medication and recom-
mended exams, had indications of poorly controlled
diabetes, and had diabetes-related complications. This
study used secondary data sources and received an
exemption from the New England Institutional Review
Board.
Estimating prevalence of diagnosed and undiagnosed
diabetes
The approach to estimate prevalence of diagnosed and
undiagnosed diabetes by population age (20–34, 35–44,
45–54, 55–59, 60–64, 65–70, and over 70), sex, insurance
type (commercial, Medicare, Medicaid, and uninsured),
and state is documented elsewhere, though detailed preva-
lence estimates by insurance type have not been previ-
ously published [3, 4, 10]. Using the 2012 American
Community Survey (ACS, n = 2,375,715), we constructed
a population file where each person residing in the
community was matched with a similar person from the
combined 2011 and 2012 Behavioral Risk Factor Surveil-
lance System (BRFSS, n = 982,154) and each person resid-
ing in a nursing home was matched with a similar person
from the 2004 National Nursing Home Survey (NNHS,
n = 14,017). Detailed information on file construction is
published elsewhere, but the ACS-BRFSS match criteria
used state, age, sex, race/ethnicity, medical insurance
status, and household income [3, 4]. The ACS-NNHS
match criteria used age, sex, and race/ethnicity. The
2011 and 2012 BRFSS files were combined to increase
sample size and assume little change in diabetes diagnosis
rates between 2011 and 2012 controlling for patient
demographics. The 2004 NNHS is the most recently avai-
lable person-level file for the nursing home popula-
tion, but the underlying rate of diagnosed diabetes was
adjusted to reflect a 2011 national study that found dia-
betes prevalence was close to 33% among nursing home
residents [11].
Diagnosed diabetes status (and hypertension and hyper-
lipidemia status) from BRFSS was determined based on
previously having been told by a health professional that
the respondent had the condition. Diabetes status from
NNHS was determined by ICD-9 diagnosis code (250.xx);
hypertension and hyperlipidemia status were determined
by ICD 401.xx and 272.xx, respectively. Applying ACS
sampling weights provides state-level estimates of adults
with diagnosed diabetes and prevalence of conditions such
as hypertension and hyperlipidemia among this popula-
tion by demographic and insurance type.
To estimate prevalence of undiagnosed diabetes by
state, age group, sex, and insurance type, we extrapolated
national rates to states using the detailed state population
characteristics available in the constructed ACS-BRFSS-
NNHS file. We first analyzed national data in the com-
bined 2009–2010 and 2011–2012 files of the National
Health and Nutrition Examination Survey (NHANES)
for adults who (a) had not previously been told by a health
professional they had diabetes; (b) were not taking insulin;
(c) were not pregnant; and (d) had laboratory results
for hemoglobin A1c, fasting plasma glucose test, 2-h oral
glucose tolerance test, or a combination of tests. We esti-
mated a logistic regression where the dependent variable
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was diabetes (n = 649) as determined by laboratory results
(see Additional file 1) exceeding thresholds for diabetes,
versus no diabetes (n = 9,296). The explanatory variables
were age group, sex, race/ethnicity, body weight category,
insurance type, current smoker, year, and previous history
or diagnosis of asthma, arthritis, heart attack, stroke, can-
cer, hypertension, hypercholesterolemia, and cardiovascu-
lar disease. We applied regression results (see Additional
file 1) to the constructed ACS-BRFSS-NNHS 2012 popu-
lation file to estimate the overall prevalence of undiag-
nosed diabetes by state.
Estimating prevalence of T2DM among the insured
population
We analyzed 2011–2012 medical and pharmacy claims for
commercially insured adults in OptumInsight’s de-identified
Normative Health Information (dNHI) database) (n = 29,
948,496), for the Medicare population using the 2011 Medi-
care Standard Analytical File 5% sample (n = 2,805,812), and
for the Medicaid population using the 2008 Mini-Max file
(n = 3,095,634). All analyses were done by state, age, and sex.
The dNHI database consists of longitudinally linked and
de-identified individual-level data from one of the nation’s
largest private insurance plans. The Medicare extract con-
tains medical and prescription claims. Mini-Max is a 5%
sample of the Medicaid Analytic eXtract data-a set of
person-level data files on service utilization and payments
for more than 60 million Medicaid enrollees extracted
from the Medicaid Statistical Information System. Patients
analyzed in each of these databases were continuously en-
rolled in a fee-for-service coverage type plan with no more
than one gap in enrollment of up to 45 days during the
measurement year for the commercially insured popula-
tion, and were enrolled for all 12 months for the Medicare
and Medicaid populations.
We identified patients with diabetes if the patient had at
least one emergency department visit or hospitalization or
two separate ambulatory visits with a diabetes diagnosis
(ICD-9 of 250.xx) submitted during the year, or if the pa-
tient used insulin or other diabetes-related medications.
Sample inclusion and exclusion criteria and the algorithm
for distinguishing whether a patient had type 1 or type 2
diabetes are described in Additional file 1. Patients with a
diagnosis of gestational diabetes were excluded. This ana-
lysis assumes that within strata defined by age group and
sex, the proportion of diabetes cases that are T2DM
remained relatively constant between 2012 and 2008 for
the Medicaid population and between 2012 and 2011 for
the Medicare population.
Estimating the proportion of T2DM patients receiving
medication and exams
Using pharmacy claims from the dNHI, Medicaid Mini-
MAX data, and Medicare Part D files for each population
strata, we calculated the percentage of patients with claims
for insulin, non-insulin injectables, or oral antidiabetic
agents. We calculated the percentage of patients with at
least one claim for anti-hypertensive medications, statins,
and angiotensin-converting enzyme (ACE) inhibitors/
angiotensin II receptor blockers (ARB). Using procedure
codes (see Additional file 1) we calculated the percentage
of patients in each population stratum with indication of
at least one cholesterol screening test, urine albumin test,
or retinal eye exam during the year. These medications
and exams are measures recommended by the HEDIS
Comprehensive Diabetes Care 2012, and HEDIS is the
source of the drug codes and procedure codes used.
Estimating the characteristics and medical expenditures
of treated T2DM patients by controlled status
Whether people have their diabetes under control is
generally determined by hemoglobin A1c levels – with
A1c < 7% often considered tight control, A1c > 9%
considered uncontrolled, and recommended individual
patient targets as high as 8.5% depending on a patient’s
circumstances [1]. Lab results with A1c values were avail-
able only for a subset of the commercially insured patients
and unavailable for Medicare and Medicaid beneficiaries.
Therefore, to identify patients with uncontrolled diabetes,
we used ICD-9 diagnosis codes of 250.x2 and 250.x3
in any claim during the year. For discussion purposes, we
refer to “uncontrolled” or “poorly controlled” status for
anyone with an ICD-9 code indicating uncontrolled dia-
betes at some point during the year, and use the term
“controlled” to define patients with no indication of un-
controlled diabetes. Use of one claim for uncontrolled
could overestimate the number of patients with uncon-
trolled diabetes; however, use of a diagnosis code rather
than A1c results could also miss some patients with
uncontrolled diabetes, so there are potentially errors
in both directions. Later we discuss the limitations of
using ICD-9 versus A1c to define uncontrolled status.
We used primary ICD-9 diagnosis codes (see Additional
file 1) in medical claims to identify the presence of eight
categories of diabetes complications: neurological symp-
toms, peripheral vascular disease, cardiovascular disease,
renal complications, endocrine/metabolic complications,
ophthalmic complications, other complications, and ortho-
pedic problems. Using medical claims to indicate comorbid-
ity presence could undercount prevalence of complications.
Diabetes is one of multiple risk factors for these compli-
cations, and we report total medical expenditures by cat-
egory because estimating the proportion of complications
attributable to diabetes is beyond the scope of this study.
We calculated the total annual medical expenditures and
pharmacy expenditures for all medical conditions, with all
costs inflated to 2012 dollars using the medical and phar-
macy cost components of the Consumer Price Index.
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Results
Diabetes prevalence
We estimate that close to 25.3 million insured adults
(age 20 or older) in the US had diabetes in 2012 (Fig. 1,
Table 1). This includes over 18.3 million adults with
diagnosed diabetes and 6.9 million undiagnosed. Of the
insured, diagnosed population, approximately 16.9 million
(about 92%) had T2DM, and 1.45 million had type 1
diabetes. The percent T2DM ranged from 87.1% for
the commercially insured population to 97.6% for the
Medicare population, and across the insured population
ranged from approximately 88% in Utah to 95% in
New Mexico (see Additional file 2 for all state-level esti-
mates). The proportion of undiagnosed diabetes cases
that are T2DM is unknown. Applying age-specific percent
T2DM rates to the undiagnosed diabetes population
suggests 6.3 million of the 6.9 million insured adults with
undiagnosed diabetes probably have T2DM, though this
is likely a lower bound for the proportion of T2DM.
California (with 12% of the nation’s adult population)
has an estimated 3.4 million people with diabetes (11%
of the national total) including over 1 million with un-
diagnosed diabetes. Estimates of undiagnosed diabetes
prevalence are based on the presence of risk factors
among the population not diagnosed with diabetes.
Alaska had the highest estimated proportion of diabetes
cases that are undiagnosed, at 38%, whereas West
Virginia (a state with high prevalence of diagnosed
diabetes) had the lowest estimated proportion (20%)
of cases undiagnosed.
Among those with diagnosed diabetes, 14% nationwide
were without medical insurance in 2012 (pre Affordable
Care Act), with this percentage ranging from a high of
21% in Louisiana to lows in the 5–6% range for Hawaii,
Massachusetts, and Washington, DC.
Exams and medication use
The medical claims analysis found that among the popu-
lations of insured adults diagnosed with T2DM, 82% had
a medical claim for at least one A1c test during the
year-ranging from 64% of the Medicaid population to
86% of the Medicare population (Table 2). Appro-
ximately 13% had at least one FPG test, and 76% had
their cholesterol levels tested (ranging from 81% for
Medicare to 58% for Medicaid). Only 57% of Medicare
patients and 33% of commercially insured patients had
claims indicating an eye exam during the year, with data
unavailable for Medicaid patients. The calculated low
rates for eye exams could reflect that some commercially
insured patients potentially have a separate eye care plan
or pay out-of-pocket, so not all eye exams are captured
in claims data. Half (50%) of patients had claims for a
urine albumin test. While not directly comparable, self-
reported data from national surveys suggest 68.5% of
all adults with diagnosed diabetes (type 1 and type 2,
insured and uninsured) had two or more A1c tests in
2010; 62.8% had a dilated eye exam; and 85.6% took
medication for diabetes (pills, insulin, or both) [2].
Prescription claims for patients with diagnosed T2DM
indicate 77% received medication for diabetes (73% for
Fig. 1 Insured adults with diabetes, 2012
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Medicare, 75% for Medicaid, and 82% for commercially
insured). Rates ranged from 70% treated with medica-
tion in New Jersey to 82% in Utah. Among Medicare pa-
tients, 76% of the age 65–74 population had claims for
diabetes medication versus 71% of the population age 75
and older. Overall, 46% had claims for metformin, 23%
had claims for insulin, and 29% had claims for sulfo-
nylureas, with smaller percentages of patients having
claims for other diabetes single therapy or combination
medications. Rates varied by state even within each insur-
ance type. While 90% of commercially insured people
with diagnosed T2DM in California received medica-
tion, the percentages were substantially lower in North-
eastern states including Maine (74%), New Jersey (76%),
Massachusetts (77%), and Rhode Island and New Hamp-
shire (78%). There was even greater state variation in
Table 1 Diagnosed and undiagnosed adults with diabetes, 2012
National metrics Insured Uninsured
Total Commercial Medicarea Medicaidb
Total with diabetes 25,260,000 11,400,000 11,430,000 2,430,000 4,950,000
Diagnosed 18,340,000 8,290,000 8,280,000 1,770,000 3,740,000
Percent diabetes cases type 2 92.1% 87.1% 97.6% 89.8% 82.0%c
Adults with diagnosed type 2 diabetes 16,890,000 7,220,000 8,080,000 1,590,000 3,440,000
Undiagnosed 6,920,000 3,110,000 3,150,000 660,000 1,210,000
Percent of type 2 diabetes patients undiagnosedd 27% 27% 28% 27% 23%
Note: aDiabetes population estimates include only adults age 65 and older-including Medicaid/Medicare dual-eligible patients and veterans receiving care through
the Veterans Health Administration
bDiabetes population estimates include only adults under age 65 who participate in a government-sponsored insurance program-including Medicaid/Medicare
dual-eligible patients; veterans receiving care through the Veterans’ Health Administration; and beneficiaries enrolled in other federal or state-subsidized medical
insurance plans (e.g., Indian Health Service)
cThe percent type 2 was estimated using age-specific proportions of type 2 among the insured population
dUndiagnosed cases in each age group are assumed to have the same proportion type 2 as diagnosed cases in each age group
Table 2 Diabetes management of insured adults with diagnosed type 2 diabetes
Treatment metrics Total insured Commercial Medicare Medicaid
Annual glucose testing
% receiving A1c 82% 80% 86% 64%
% receiving FPG 12% 10% 14% 15%
% receiving OGTT 0.6% 1.1% 0.2% 0.8%
Other recommended testing
% receiving cholesterol test 76% 75% 81% 58%
% receiving eye exam NA 33% 57% NA
% receiving urinary albumin test 50% 45% 55% 43%
Medication to treat diabetesa
% receiving diabetes medication 77% 82% 73% 75%
Receiving diabetes medication 12,990,000 5,930,000 5,860,000 1,200,000
Receiving metformin 46% 53% 40% 46%
Receiving insulin 23% 21% 23% 29%
Not receiving diabetes medication 3,900,000 1,290,000 2,220,000 390,000
Receiving other medications
ACE inhibitors and ARBsb 63% 60% 67% 57%
Other anti-hypertensives (e.g., diuretics) 47% 31% 62% 43%
Statins 58% 55% 64% 46%
% with hypertension 80% 72% 91% 61%
% with hyperlipidemia 76% 75% 83% 43%
Notes: aIncludes insulin, non-insulin injectables, or oral antidiabetic agents
bACE Angiotensin-converting enzyme inhibitors, ARB Angiotensin II receptor blockers
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percentage receiving medication within the Medicaid
population-ranging from 84% in Connecticut to 44% in
Arizona.
Diagnosis codes and medication claims suggest 80% of
diagnosed T2DM adults had hypertension (controlled or
uncontrolled, ranging from 91% for Medicare to 61% for
Medicaid), and 76% had hyperlipidemia (ranging from
83% for Medicare to 43% for Medicaid). Medication
claims for these diagnosed T2DM patients indicate 63%
received ACE inhibitors/ARBs, 47% received other anti-
hypertensive medications (e.g., diuretics), and 58% re-
ceived statins.
Poorly controlled diabetes, sequelae, and costs
Among diagnosed patients receiving diabetes medications,
43% had at least one medical claim during the year where
an ICD-9 code indicated the patient’s diabetes was poorly
controlled (Table 3). This estimate was similar across all
three insurance types. The presence of diabetes sequelae
was higher among the population with uncontrolled
diabetes relative to the population with no indication
of uncontrolled diabetes. Prevalence of neurological
conditions was 14 percentage points higher among the
uncontrolled diabetes population compared to the popula-
tion with no indication of uncontrolled diabetes. Similarly,
among the uncontrolled population there was higher
prevalence of renal failure (14 percentage points higher),
“other” complications (13 percentage points higher),
peripheral vascular complications (11 percentage points
higher), and endocrine/metabolic complications (10 per-
centage points higher). The Medicare population with
diagnosed T2DM had higher rates of diabetes sequelae
compared to the commercially insured and Medicaid
populations. For example, 36% of the Medicare population
with no indication of uncontrolled diabetes still had claims
indicating presence of neurological complications-versus
17% prevalence among the Medicaid and 12% among the
commercially insured populations. Among the population
with indications of uncontrolled diabetes, prevalence of
neurological complications was 52, 31, and 23% for the
Medicare, Medicaid, and commercially insured popula-
tions, respectively. Differences in complication prevalence
across insurance type and by controlled/uncontrolled sta-
tus likely contributed to the large differences in average
annual medical costs.
Total annual health care expenditures for the treated
population with controlled diabetes averaged $17,500
per patient (ranging from $13,160 for commercially
insured patients to $21,280 for Medicare patients). This
includes both diabetes- and non-diabetes-related expen-
ditures. In comparison, annual health care expenditures
averaged $22,410 for the uncontrolled population (ranging
from $19,730 for commercially insured patients to
$24,440 for Medicare patients). Adjusting the age-sex
distribution of the controlled population to match demo-
graphics of the uncontrolled population suggests that pa-
tients with uncontrolled diabetes have higher annual health
care expenditures averaging $4,860 per T2DM patient-
including $4,150 in higher medical expenditures and $710
in higher prescription expenditures (with higher prescrip-
tion expenditures associated primarily with higher costs for
insulin). Average expenditure differences between controlled
and uncontrolled were highest for the commercially insured
population ($6,680), followed by the Medicaid population
($4,360) and Medicare population ($3,430). Average differ-
ence in medical costs between controlled and uncontrolled
patients was highest for Nevada ($7,800) and Nebraska
($7,530), while New Mexico ($2,080) and California
($2,410) had the smallest excess costs (Additional file 2).
Key findings are summarized in Table 4. Close to 25.3
million adults with diabetes have medical insurance coverage,
but among these only 18.3 million are diagnosed. Of the esti-
mated 6.9 million undiagnosed, at least 6.3 million are T2DM
(suggesting 27% of people with T2DM are undiagnosed). The
large majority (92%) of diagnosed cases are T2DM, and
among the T2DM population 77% have medication claims
indicating use of diabetes medicine. Even if all type 1 patients
used diabetes medication (insulin), these numbers suggest
that at most 79% of the insured population with diabetes
used diabetes medication-a number below the 86% estimate
from self-report national survey data for all adults with diag-
nosed diabetes, both insured and uninsured [2].
Discussion
Approximately 84% of adults in 2012 with diagnosed or
undiagnosed diabetes had medical insurance. Presum-
ably these insured adults had access to care, but still an
estimated 27% of diabetes cases remained undiagnosed.
The new guidelines from the US Preventive Services
Task Force for diabetes screening of asymptomatic adults
recommend screening for adults with risk factors for dia-
betes (including all adults aged 40 to 70 years who are
overweight or obese, or who have one or more other
known risk factors for diabetes such as family history of
diabetes) [9]. If adopted and used by practitioners, in-
creased targeted screening could reduce the rate of un-
diagnosed cases among the insured population. The
Congressional Budget Office estimates that the Afford-
able Care Act will by 2017 result in 26 million people re-
ceiving medical coverage who would otherwise be
uninsured [12]. Together, increased insurance coverage
and adoption and use of broader screening guidelines
could reduce the number of undiagnosed diabetes cases.
Still, among adults with diagnosed T2DM, some appear
to have inadequate disease management. Approximately
80% of these adults have diagnosed hypertension
(whether treated or untreated), while approximately 63%
of T2DM adults have medication claims for ACE
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Table 3 Complications and expenditures for adults with type 2 diabetes receiving diabetes medications
National metrics Total insured Commercial Medicare Medicaid
Controlled diabetes 7,440,000 3,480,000 3,270,000 690,000
Controlled (%) 57% 59% 56% 58%
Presence of diabetes sequelae
Neurological complications 24% 12% 36% 17%
Peripheral vascular disease 19% 8% 32% 12%
Cardiovascular disease 80% 71% 93% 61%
Renal complications 28% 17% 40% 20%
Endocrine/metabolic complications 72% 70% 81% 38%
Ophthalmic complications 35% 21% 51% 22%
Other complications 17% 14% 20% 19%
Foot problems 7% 3% 10% 7%
Total expenditures $17,500 $13,160 $21,280 $19,000
Medical expenditures $12,980 $9,630 $15,900 $14,110
Rx expenditures $4,520 $3,530 $5,380 $4,890
Uncontrolled diabetes 5,550,000 2,450,000 2,590,000 510,000
Uncontrolled (%) 43% 41% 44% 42%
Presence of diabetes sequelae
Neurological complications 38% 23% 52% 31%
Peripheral vascular disease 30% 13% 46% 20%
Cardiovascular disease 88% 80% 96% 76%
Renal complications 42% 27% 56% 33%
Endocrine/metabolic complications 82% 82% 88% 51%
Ophthalmic complications 43% 28% 58% 33%
Other complications 30% 24% 34% 35%
Foot problems 12% 7% 17% 12%
Total expenditures $22,410 $19,730 $24,440 $23,490
Medical expenditures $17,140 $14,880 $18,900 $17,830
Rx expenditures $5,270 $4,850 $5,540 $5,660
Uncontrolled impact (percentage point or $ change)
Presence of diabetes sequelae
Neurological complications 14% 11% 16% 14%
Peripheral vascular disease 11% 5% 14% 8%
Cardiovascular disease 8% 9% 4% 15%
Renal complications 14% 10% 16% 13%
Endocrine/metabolic complications 10% 12% 7% 13%
Ophthalmic complications 8% 7% 7% 11%
Other complications 13% 10% 14% 16%
Foot problems 5% 3% 7% 6%
Total expenditures $4,910 $6,570 $3,160 $4,490
Medical expenditures $4,160 $5,250 $3,000 $3,720
Rx expenditures $750 $1,320 $160 $770
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inhibitors/ARBs and 47% have medication claims for
diuretics or other anti-hypertensive medications. Appro-
ximately 76% of these adults have hyperlipidemia, yet only
58% have medication claims for statins (though other
medications might be used to treat hyperlipidemia). Only
82% of these patients had at least one A1c test during
the year (guidelines are to receive two or more) [1]. Half
received a urinary albumin test (guidelines call for an-
nual screening) [1].
The need for diabetes medications will differ by
patient and can change over time. Approximately
77% of diagnosed T2DM patients had claims for dia-
betes medications. Among those receiving medica-
tion, 43% had medical claims indicating uncontrolled
diabetes. Patients with indications of poor glycemic
control had higher prevalence of complications and
$4,860 higher annual health care expenditures com-
pared to a similar population with controlled gly-
cemic levels.
This study reports a large set of health outcomes for pa-
tients with T2DM at the national and state levels. We found
few studies with similar scope to compare with at the state
level. However, at the national level, our estimates
are comparable with other estimates. For instance, the
American Diabetes Association [13] reports that 90 to 95%
of diagnosed diabetes cases are T2DM, while our estimate
was 92%, ranging from 87% among privately insured to
98% among Medicare beneficiaries with diabetes. CDC re-
ported that approximately 81% of diagnosed diabetes (in-
cluding type 1 and T2DM) patients aged 18 and above in
2011 were treated with either oral drugs, insulin, or both
based on self-reported data, while we found that 77%
(T2DM only) receive medication [14]. A 2013 study
using electronic medical records found that in the
period between 2011 and 2012, 81.6% of diabetes pa-
tients had an A1c test (almost identical to our finding
of 82% receiving annual A1c test among T2DM patients).
This same study also found that 39% of the diabetes pa-
tients did not have their diabetes under control de-
fined as A1c < 7, while we found 43% uncontrolled
based on diagnosis codes [15].
Study strengths and limitations
This study analyzed medical claims for large samples
of commercially insured, Medicare, and Medicaid popula-
tions to provide insight on treatment patterns, prevalence
Table 3 Complications and expenditures for adults with type 2 diabetes receiving diabetes medications (Continued)
Controlled (age-sex-adjusted to uncontrolled population)
Total expenditures $17,550 $13,050 $21,010 $19,130
Medical expenditures $12,990 $9,560 $15,630 $14,170
Rx expenditures $4,560 $3,490 $5,380 $4,960
Uncontrolled impact (age-sex-adjusted)
Total expenditures $4,860 $6,680 $3,430 $4,360
Medical expenditures $4,150 $5,320 $3,270 $3,660
Rx expenditures $710 $1,360 $160 $700
Table 4 Summary metrics for diabetes diagnosis, treatment, and control
Key metrics Total insured Commercial Medicare Medicaid
Total with diabetes 25,260,000 11,400,000 11,430,000 2,430,000
Total undiagnosed 6,920,000 3,110,000 3,150,000 660,000
Percent of type 2 diabetes patients undiagnoseda 27% 27% 28% 27%
Diagnosed 18,340,000 8,290,000 8,280,000 1,770,000
Diagnosed type 1 1,450,000 1,070,000 200,000 180,000
Diagnosed type 2 16,890,000 7,220,000 8,080,000 1,590,000
% not receiving diabetes medication 23% 18% 27% 25%
Not receiving diabetes medication 3,900,000 1,290,000 2,220,000 390,000
Receiving diabetes medication 12,990,000 5,930,000 5,860,000 1,200,000
Poorly controlled diabetes 5,550,000 2,450,000 2,590,000 510,000
Controlled diabetes 7,440,000 3,480,000 3,270,000 690,000
% poorly controlled 43% 41% 44% 42%
Average increase in medical expenditures for uncontrolled diabetes $4,860 $6,680 $3,430 $4,260
aUndiagnosed cases in each age group are assumed to have the same proportion type 2 as diagnosed cases in each age group
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of diabetes-related complications, and medical and pre-
scription medicine expenditures. The use of medical
claims provides a comparison to diabetes management
statistics based on self-reported surveys. Study limitations
include the following:
Analysis of medical claims was restricted to a fee-for-
service population as medical claims are often incom-
plete for patients in capitated managed care plans. It is
unclear how this might bias study results. Medicare
patients with poorer health might choose a fee-for-
service plan over a managed care plan because it gives
them greater access to physicians not in a managed care
network, but this is unlikely to affect diabetes detection,
treatment, and control. Medicaid patients often have less
ability to select whether they are in a managed care or
fee-for-service type arrangement (with plan type often
determined by state policy).
Uncontrolled status was determined by diagnosis code
and not independent lab results. While laboratory results
are available for a subset of the commercially insured
T2DM patients, Medicare and Medicaid files do not
contain laboratory results. To create a consistent defin-
ition of diabetes control across insurance types, we iden-
tified patients with controlled diabetes as those who
were not diagnosed with uncontrolled diabetes (ICD-9
code 250.×2 or 250.×3) during the study year. For the
subset of commercially insured T2DM patients for
which we had both ICD-9 and A1c information, we
performed additional correlation analyses to assert the
strength of the association between the two measures
of diabetes control. We found a statistically significant
and positive correlation between ICD-9- and A1c-based
case identification measures (Spearman rank correlation
coefficients of 0.22 [P < 0.001] for A1c > 9% as uncon-
trolled). However, the low correlation suggests that ICD-9
indications of uncontrolled diabetes, as currently coded,
are a weak proxy for actual A1c results. Chi-square statis-
tics were also significant. Patients who are sicker tend to
have more touch points with the health care system and
thus generate more medical claims, so there is a higher
likelihood that they might be categorized as having
uncontrolled diabetes. This could bias high the estimated
expenditure impact associated with uncontrolled diabetes.
Medical claims data were unavailable for care provided
through the Veterans Health Administration, Indian
Health Services, and other providers. Estimates for the
number of adults age 65 or older with diabetes are
counted under Medicare-including veterans receiving care
through the VHA. Estimates for the number of adults
under age 65 with diabetes who receive health care
through a government-sponsored program are counted
under Medicaid-including Medicaid dual-eligible patients,
veterans receiving care through the VHA, and other
government-sponsored plans such as IHS.
The OptumInsight dNHI claims data, while nationally
representative of the privately insured patient popula-
tion, might not be representative for some states where
United Healthcare and other insurers represented in
dNHI have smaller market share. Consequently, for this
analysis we estimated outcomes using dNHI data in each
state by age and gender and then weighted outcomes
based on the age and gender distribution of privately in-
sured people in each state in our constructed state popu-
lation file. States with small sample size in the dNHI are
Alaska, Hawaii, Montana, South Dakota, Vermont, and
Wyoming. When the sample was less than n = 30 pa-
tients for a particular age-gender strata, we used na-
tional outcomes rather than state outcomes for that
demographic group. Hence, for these states the metrics
reported in this paper for the commercially insured
population are biased toward the national average.
The analysis relied in part on self-reported data col-
lected through surveys (American Community Survey,
Behavioral Risk Factor Surveillance System, and National
Health and Nutrition Examination Survey). Self-reported
household income, body weight, smoking status, and
other patient characteristics can be unreliable.
For some data sources we combined data from mul-
tiple years between 2008 and 2012 to increase sample
size. Combining data across years makes the implicit
assumption that diagnosis rates and the proportion of
diagnosed diabetes cases that are T2DM remained
relatively constant over this period.
These data limitations suggest possible areas for im-
provement. For example, a centralized source for patient
information-such as all-payer claims databases that some
states are developing-will facilitate comparing diabetes-
related outcomes across geographic locations and payers,
thus facilitating the identification of populations doing
well (to identify possible best practices) and identifying
populations doing poorly (to identify needs). This study
used ICD-9 diagnosis codes and self-reported data in
surveys, but such sources can be unreliable. Increased
availability of data from electronic health records could
provide more reliable data for future benchmarking.
Conclusions
The large number of patients with undiagnosed diabetes
and large numbers of diabetes patients not receiving
medication (for diabetes, hypertension, and hyperlipi-
demia) or monitoring exams indicate a need for greater
commitment by providers to closely monitor their pa-
tients and be more aggressive in following standards of
medical care. These findings underscore that, among an
insured population that presumably has good access to
professional care, too many people have undiagnosed
diabetes and those whose diabetes is diagnosed often
require better management of their disease. The uninsured
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are more likely than their insured peers with similar
demographics to be undiagnosed, and having insurance is
associated with improved control of diabetes [16–18].
Consequently, expanding insurance coverage through the
Affordable Care Act is part of the solution to the lack of
diagnosis and diabetes control challenge. While Medicare
patients are the most costly overall to treat, our findings
suggest the medical expenditure gap between controlled
and uncontrolled diabetes is higher for commercially
insured patients than for government-insured patients.
Additional research could help identify why diabetes-
related outcomes differ substantially by state and insu-
rance type, with the goal to inform policies or practices
that could help improve diabetes outcomes among low-
performing populations.
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